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The International Peripheral T-cell Lym-
phoma Project is a collaborative effort to
better understand peripheral T-cell lym-
phoma (PTCL). A total of 22 institutions
submitted clinical and pathologic mate-
rial on 1314 cases. One objective was to
analyze the clinical and pathologic fea-
tures of 340 cases of PTCL, not otherwise
specified. The median age of the patients
was 60 years, and the majority (69%)
presented with advanced stage disease.
Most patients (87%) presented with nodal
disease, but extranodal disease was pres-
ent in 62%. The 5-year overall survival
was 32%, and the 5-year failure-free sur-
vival was only 20%. The majority of pa-
tients (80%) were treated with combina-
tion chemotherapy that included an
anthracycline, but there was no survival
advantage. The International Prognostic
Index (IPI) was predictive of both overall
survival and failure-free survival
(P < .001). Multivariate analysis of clini-
cal and pathologic prognostic factors,
respectively, when controlling for the IPI,
identified bulky disease (> 10 cm), throm-
bocytopenia (< 150  109/L), and a high
number of transformed tumor cells
(> 70%) as adverse predictors of sur-
vival, but only the latter was significant in
final analysis. Thus, the IPI and a single
pathologic feature could be used to
stratify patients with PTCL-not otherwise
specified for novel and risk-adapted thera-
pies. (Blood. 2011;117(12):3402-3408)
Introduction
Peripheral T-cell lymphoma (PTCL) and natural killer/T-cell lym-
phoma (NKTCL) are an uncommon and heterogeneous group of
disorders that compose 5% to 20% of all non-Hodgkin lymphomas
(NHLs) in different parts of the world.1,2 In recent years, the
incidence of PTCL and NKTCL in the United States has increased
by almost 3-fold with an annual increase of 3.8%, whereas the
incidence of B-cell lymphoma and Hodgkin lymphoma has been
relatively stable.3,4
One of the most common subtypes of PTCL is a heteroge-
neous group of nodal and extranodal mature T-cell lymphomas
that do not correspond to any of the specifically defined T-cell
entities in the World Health Organization classification,1 and are
therefore called PTCL, not otherwise specified (NOS). Uncom-
mon variants of PTCL-NOS include lymphoepithelioid (Lennert)
lymphoma, and cases with a follicular or T-zone pattern of
growth.1 Over the last 12 years, several clinical studies have
attempted to identify the clinical and pathologic features of
prognostic importance in PTCL-NOS, but the number of cases
in these studies was generally small and the findings have been
inconsistent or unconfirmed.5-13
The International Peripheral T-cell Lymphoma Project was
undertaken as a large retrospective study of PTCL and NKTCL in
North America, Europe, and Asia with the goal of better character-
izing this group of NHL. One objective of was to analyze the
clinical and pathologic features of the 340 cases of PTCL-NOS in
the study, and to determine the important prognostic factors for this
uncommon entity.
Methods
Twenty-two institutions in North America, Europe, and Asia participated in
the study (supplemental Appendix, available on the Blood Web site; see the
Supplemental Materials link at the top of the online article). Approval for
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the study was obtained from the Institutional Review Board at the
coordinating center (University of Nebraska Medical Center) and at each
participating center per the institutional policy. The cases selected for the
study were previously untreated patients 19 years of age or older with de
novo PTCL or NKTCL, excluding mycosis fungoides and Se´zary syn-
drome, who were diagnosed between January 1, 1990 and December 31,
2002. The patients were consecutive from each institution and were
required to have adequate tissue biopsies for diagnosis and classification.
Patients with only needle aspiration cytology specimens were excluded. At
each institution, the local pathologist reviewed the diagnostic pathology
slides and reports for each case, and recorded the results of local
immunophenotypic, cytogenetic, and molecular genetic studies that had
been performed in the initial diagnosis of the case on a standard
phenotype datasheet. The local pathologist also selected representative
slides and a formalin-fixed tissue block from each case to submit for
regional review and more detailed immunophenotyping. Cases in which
the tissue blocks were exhausted or no longer available for study were also
acceptable if the slides and immunostains or flow cytometric data were
available for review and adequate for diagnosis and classification. Clinical
characteristics of the patients, including treatment data and follow-up
information, were also required.
From each institution, the phenotype datasheets, diagnostic slides, and
tissue blocks were sent to one of 5 regional centers for review and
evaluation by an expert hematopathologist. These centers included Omaha,
NE (D.D.W.); Leeds, United Kingdom (K.A.M.); Wu¨rzburg, Germany
(T.R.); Bologna, Italy (S.P.); and Nagoya, Japan (S.N.). A standard panel of
immunostains was performed on each case, including CD20, CD2, CD3,
CD4, CD5, CD8, CD30, CD56, TCR-, TIA-1, and Ki67, and in situ
hybridization stains for Epstein Barr virus–encoded RNAs (EBERs). An
immunostain was considered positive if more than 20% of the tumor cells
stained. Other immunostains, polymerase chain reaction analyses, and
fluorescence in situ hybridization cytogenetic studies were performed as
needed, and all cases were diagnosed according to the criteria of the
World Health Organization classification.1 The percentages of transformed
tumor cells (blasts), and tumor cells expressing CD30 or Ki67, were also
estimated in 5% increments for each case, as were the percentages of
background nontumor cells expressing either CD4 or CD8. The number
of cells staining for EBERs was evaluated semiquantitatively by
counting positive cells in the 10 most positive fields using a 10 ocular
lens and a 20 objective, and calculating the average number per field (f):
0/f  0;  1/f  1; 1 to 9/f  2; 10 to 50/f  3; and  50/f  4.
The results of these studies and the diagnosis were recorded by the regional
expert on standard phenotype and diagnosis datasheets, respectively, for
each case.
Panels of 4 expert hematopathologists, drawn from the contributing
local sites and regional centers, then traveled to the regional centers to
review the cases. The composition of the panels differed at the various
regional centers. At each center, the diagnostic slides for each case were
classified independently by each expert according to the criteria of the
World Health Organization classification.1 The initial diagnosis was based
on examination of the hematoxylin and eosin– and/or Giemsa-stained
slides, the immunostains, and the phenotype datasheets, but with only
limited clinical information from the time of initial diagnosis, including
the anatomic biopsy site and the site of the largest tumor mass (ie,
diagnosis 1). After recording this diagnosis, the expert was presented
with the entire clinical datasheet and a second diagnosis was rendered
(ie, diagnosis 2). The previous diagnosis could not be changed based on
the clinical information subsequently revealed. If a case was considered
unclassifiable, the expert was required to give a reason, such as inadequate
material, poor slide preparation, additional immunophenotyping needed,
additional information needed, or other reasons. Each expert also estimated
the percentage of transformed tumor cells (blasts) in 5% increments for
each case. The median of the estimates of the 4 panel experts and the
regional expert was used as the percentage of transformed cells for
each case. Approximately 50 to 60 cases were reviewed by each expert
each day.
In addition to the independent diagnosis rendered by each of the
4 expert hematopathologists, a consensus diagnosis was also reached in
each case. A consensus was considered to have been reached if at least 3 of
the 4 experts on the panel agreed on the second diagnosis (diagnosis 2). All
cases without a consensus diagnosis and all unclassifiable cases were jointly
reviewed on a multiheaded microscope and discussed by the 4 experts in a
daily consensus conference, and an attempt was made to reach a consensus
diagnosis. If additional sections, immunostains, molecular or cytogenetic
studies, or other information was required, a diagnostic algorithm was
developed by the panel and the additional materials or data were obtained, if
possible, and reviewed at a subsequent consensus conference at the center.
If the additional materials or data could not be obtained during the site visit,
the required materials and information were subsequently sent to the expert
hematopathologist at the regional center who arbitrated the case based on
the algorithm.
The clinical information for each case was abstracted from the medical
record and recorded on a standard clinical datasheet for computerized data
entry. These data included coded patient and site identifiers, sex, ethnicity,
date of birth, site of the diagnostic biopsy, other sites of disease, and Ann
Arbor stage. Additional data recorded included the symptoms at diagnosis,
site and diameter of the largest tumor mass, performance status, and a
history of prior immunosuppressive therapy or immune system disorder.
Laboratory data recorded included hemoglobin, platelet count, white blood
cell count, presence of circulating lymphoma cells, and serology for HIV
and human T-lymphotropic virus, type-1 (HTLV-1). The serum lactate
dehydrogenase, 2-microglobulin, and C-reactive protein levels, and the
presence of hypercalcemia, hypogammaglobulinemia, hypergammaglobu-
linemia, monoclonal serum immunoglobulin, hemolytic anemia, and he-
mophagocytic syndrome were recorded. The initial therapy and response,
details of remission, progression or relapse, and subsequent therapies, along
with survival status and cause of death, were recorded. In some cases,
sufficient data were not available for inclusion in some of the clinical or
survival analyses.
Completed clinical and pathology datasheets were reviewed and edited
to detect any inconsistencies, and additional information or clarification
was obtained when needed. After editing, the clinical and pathology data
were entered into a computer for data analysis. The International Prognostic
Index (IPI)14 was used to stratify patients, and a new prognostic model for
PTCL-NOS was evaluated.9 Treatment outcome was determined by
overall survival (OS) and failure-free survival (FFS). OS was defined as
the time from diagnosis to death from any cause, with surviving patient
follow-up censored at the last contact date. FFS was defined as the time
from diagnosis to the first occurrence of progression, relapse after
response, or death resulting from any cause. Follow-up of patients not
experiencing any of these events was censored at the date of last contact.
Estimates of OS and FFS distributions were calculated using the method
of Kaplan and Meier,15 and time-to-event distributions were compared
using the log-rank test.16 Clinical and prognostic factor comparisons
were performed using the 2 or Fisher exact test. Multivariate analysis
was performed with the Cox proportional hazards regression model
using stepwise selection.
Results
Of the 1314 eligible cases submitted, a diagnosis of PTCL or
NKTCL was made in 1153 cases (87.8%), and 340 of these were
PTCL-NOS (29.5%). Of the latter, 101 cases (30%) were from
North America, 135 (40%) were from Europe, and 104 (30%)
were from Asia. Among the 340 PTCL-NOS cases, 301 (88.5%;
26.1% of all cases) were classified as unspecified PTCL,
28 (8.2%; 2.4%) as lymphoepithelioid (Lennert) PTCL, 6 (1.8%;
0.5%) as follicular PTCL, and 5 (1.5%; 0.5%) as T-zone PTCL.
The immunophenotypic features of the cases are shown in Table
1. Immunostaining for TCR- was not very useful because
many cases of presumed - type failed to stain. The EBER
cells were background small and large B cells. Lymphoepitheli-
oid PTCL was more likely to express CD8 and TCR-, and less
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often expressed CD30. There were no significant immunopheno-
typic differences for cases that presented with extranodal
disease only, or by geographic region.
Diagnostic accuracy
Two diagnoses were made by each of the 4 expert hematopatholo-
gists in each case based mainly on the histology, immunopheno-
type, and molecular genetic data (diagnosis 1), and with the
additional complete clinical data (diagnosis 2). A consensus
diagnosis of PTCL-NOS was reached in 71% of the cases by this
review, and the agreement rate of diagnosis 2 from the experts with
the consensus diagnosis of PTCL-NOS was 75%. The most
common disagreements with the consensus diagnosis were angio-
immunoblastic T-cell lymphoma (34%) and anaplastic large cell
lymphoma, ALK-negative (13%). However, the agreement rate of
diagnosis 2 from the experts with the consensus diagnosis of
lymphoepithelioid PTCL was only 58%, with the most common
disagreement being PTCL, unspecified (50%).
A change in the diagnosis of PTCL-NOS (diagnosis 1) to the
correct (consensus) diagnosis after consideration of the clinical
data occurred in 154 cases, with 105 of these cases (68%) changed
to a diagnosis of adult T-cell leukemia/lymphoma with knowledge
of the HTLV-1 status. Other common changes after consideration
of the clinical data included angioimmunoblastic T-cell lymphoma
(7%) and enteropathy-associated T-cell lymphoma (11%). Change
from another diagnosis to the consensus diagnosis of PTCL-NOS
also occurred in 14 cases, the most common being angioimmuno-
blastic T-cell lymphoma (43%). The presence or absence of clinical
features typical of angioimmunoblastic T-cell lymphoma, such as
hypergammaglobulinemia, skin rash, autoantibodies, or autoim-
mune cytopenias, appeared to influence the diagnosis in borderline
cases. All cases reclassified as entities other than PTCL-NOS were
excluded from further analysis.
Clinical features
The clinical features of the 340 patients with PTCL-NOS are
presented in Table 2. The median age for the patients was 60 years
(range, 19-87 years), and the male-to-female ratio was 1.9:1. The
majority of patients (69%) had advanced stage (III/IV) disease.
Only nodal disease was present in 38%, nodal and extranodal
disease in 49%, and extranodal disease only was present in 13% of
the patients. Hepatomegaly was noted in 17% and splenomegaly in
24% of the patients. Other common extranodal sites included the
skin (16%), subcutaneous tissue (6%), and the lungs (8%). A
history of prior immunosuppressive therapy or immune system
disorder was reported in 13 and 9 patients, respectively, and only
one patient had HIV infection. Other findings included a hemoglo-
bin of less than 110 g/L (22%), circulating tumor cells (10%),
elevated serum 2-microglobulin (36%), C-reactive protein (50%)
or calcium (5%) levels, hypogammaglobulinemia (9%), monoclo-
nal serum immunoglobulin (4%), hemolytic anemia (3%), and
hemophagocytic syndrome (3%).
Treatment and outcome
The median follow-up duration was 3.1 years, and the 5-year OS
for the entire group was 32%, whereas the 5-year (FFS) was only
20% (Figure 1). The OS at 1 and 3 years was 69% and 41%,
respectively, whereas the corresponding FFS was only 46% and
25%, respectively. The majority of patients (80%) received combi-
nation chemotherapy containing an anthracycline, whereas the rest
received combination chemotherapy without an anthracycline
(7%), single-agent therapy (4%), or no chemotherapy (9%). The
complete remission rate for those receiving an anthracycline-
containing regimen was 56% and the 5-year OS was 36%, but the
5-year FFS was only 22%. There was no survival advantage for
patients with PTCL-NOS who received combination chemotherapy
containing an anthracycline compared with those receiving combi-
nation chemotherapy without an anthracycline.17 There were no
differences in complete response rates or survival by geographic
region. However, initial radiation therapy improved the OS of
patients with stage 1 disease who also received chemotherapy






CD2 86 (211/244) 100 (13/13)
CD3E 93 (238/255) 88 (14/16)
CD4 66 (140/213) 64 (9/14)
CD5 69 (170/245) 87 (13/15)
CD8 19 (48/250) 44* (7/16)
CD30 32 (69/217) 12* (2/16)
CD56 6 (13/219) 8 (1/13)
TCR- 38 (72/190) 91* (10/11)
TIA-1 32 (62/195) 46 (6/13)
EBER
1-4 30 (67/222) 31 (4/13)
3-4 14 (30/222) 0 (0/13)
*P  .05 vs all other PTCL-NOS.
Table 2. Clinical features of patients with PTCL-NOS
Characteristic Value







B symptoms, % (n/N) 35 (118/340)
Performance status 2, % (n/N) 18 (60/334)
Elevated serum LDH, % (n/N) 49 (158/323)
Extranodal sites 1, % (n/N) 29 (99/340)
Bone marrow positive, % (n/N) 21 (68/322)
Bulky disease 10 cm, % (n/N) 7 (19/285)
Platelets 150  109/L, % (n/N) 24 (64/266)
Hypergammaglobulinemia, % (n/N) 14 (29/201)
LDH indicates lactate dehydrogenase.
Figure 1. OS and FFS of 340 patients with PTCL-NOS.
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(n  25) compared with those who received only chemotherapy
(n  16; Figure 2). The result was similar for FFS (P  .06). At the
close of the study, 68% of the patients had died and only 9% were
in remission at the time of death.
Clinical prognostic factors
All of the prognostic factors in the IPI were highly significant
predictors of OS and FFS (P  .001), and the IPI was predictive of
both OS and FFS (Figure 3; Table 3). The more recently described
prognostic index for PTCL-NOS (PIT), which includes 3 character-
istics of the IPI (age, performance status, and lactate dehydroge-
nase level) and bone marrow involvement, was also predictive of
survival (Figure 4; Table 3). However, bone marrow involvement
was not a robust predictor of OS (P  .03) or FFS (P  .06) in our
patients, and the PIT does not appear to be superior to the IPI in
predicting the survival of patients with PTCL-NOS. Only one
group with relatively good FFS was identified using either model.
We also evaluated other potential prognostic factors by univari-
ate analysis and the following were adverse predictors of OS and
FFS, respectively: B symptoms (P  .004; P  .014), bulky dis-
ease  10 cm (P  .005; P  .004), elevated serum C-reactive
protein (P  .018; P  .008), circulating tumor cells (P  .001;
P  .001), and a platelet count of less than 150 109/L (P  .001;
P  .001). The presence of hypergammaglobulinemia was a favor-
able prognostic indicator of OS and FFS (P  .04; P  .03).
Multivariate analysis of clinical prognostic factors
By stepwise multivariate analysis, when controlling for the IPI,
only bulky disease  10 cm was still predictive of survival, with a
hazard ratio (HR) of 2.1 for OS (P  .019) and 2.5 for FFS
(P  .003). A platelet count of less than 150 109/L was also
predictive of FFS (HR 1.6, P  .016).
Figure 2. OS of patients with stage 1 PTCL-NOS who received initial radiation
therapy in addition to chemotherapy (n  25) compared with those who
received only chemotherapy (n  16).
Figure 3. Survival. OS (A) and FFS (B) of patients with PTCL-NOS (n  315)
according to the IPI.
Table 3. Survival of patients with PTCL-NOS by prognostic models
Model/no. of
risk factors Cases, % 5-year OS, % 5-year FFS, %
IPI
0/1 28 50 36
2 35 33 18
3 22 16 15
4/5 15 11 9
PIT
0 20 50 34
1 38 40 22
2 29 22 13
3/4 13 11 8
Figure 4. Survival. OS (A) and FFS (B) of patients with PTCL-NOS (n  315)
according to the PIT.
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Pathologic prognostic factors
We also evaluated a variety of pathologic features as possible
prognostic factors by univariate analysis, and the following were
adverse predictors of OS and FFS, respectively: Ki67 proliferation
more than 25% (75% of cases; P  .001; P  .009), transformed
tumor cells more than 70% (31%; P  .008; P  .12), significant
numbers of Epstein-Barr virus (EBV)-positive B cells (EBERs
3-4, 14%; P  .044; P  .48), and CD56 expression (6%;
P .05; P .04) and CD30 expression (32%; P .053; P .059)
by more than 20% of the tumor cells. Interestingly, significant EBV
positivity was predictive of adverse survival only in patients
younger than 60 years (P  .007; P  .18) but was not related to a
history of immunosuppressive therapy or immune system disorder.
The following pathologic features were favorable predictors of
OS and FFS, respectively: lymphoepithelioid (Lennert) variant
(8.2%; P  .003; P  .026; Figure 5) and background CD8
T cells more than 10% (23%; P  .08; P  .005). There were no
significant differences in the clinical prognostic factors between
patients with the lymphoepithelioid (Lennert) variant and the
others with PTCL-NOS (results not shown). Pathologic features
that were not predictive of survival were the tumor T-cell pheno-
type (CD4 or CD8, or CD4	 and CD8	) and a cytotoxic
phenotype (TIA1).
Multivariate analysis of pathologic prognostic factors
By stepwise multivariate analysis, when controlling for the IPI,
only transformed tumor cells more than 70% were predictive of OS
(HR 1.7, P  .019), and no pathologic features were predictive
of FFS. The expert pathologists were correct in their estimate of
transformed tumor cells more than 70% in 88% of these cases.
Final multivariate analysis of significant clinical and pathologic
prognostic factors
By stepwise multivariate analysis, when controlling for the IPI and
considering only bulky disease  10 cm, a platelet count less than
150 109/L, and transformed tumor cells more than 70%, only the
latter was predictive of OS (HR 2.2, P  .0002) and FFS
(HR 1.6, P  .014).
Discussion
In our study of 1153 cases of PTCL and NKTCL, the 340 cases of
PTCL-NOS represented 29.5% of all cases. This finding is in
keeping with other smaller studies5-7,12,18-23 in which PTCL-NOS
was usually the most frequent subtype, composing 17% to 59% of
all cases. To date, our study is one of the largest reported series of
PTCL-NOS. In our series, lymphoepithelioid (Lennert) PTCL was
the most common special variant of PTCL-NOS, composing
2.4% of all cases and 8.2% of PTCL-NOS. This latter finding is in
keeping with other studies of PTCL-NOS,6,8,9,19 which have
reported this variant in 2% to 13% of cases. The diagnostic
accuracy of PTCL-NOS, that is the agreement rate of the ex-
pert hematopathologists with the consensus diagnosis, in our study
was only 75%, similar to that reported by others.6,12 Detailed
clinical information was important for the correct diagnosis of
PTCL-NOS, and particularly information on the HTLV-1 status
of the cases from Japan. Without this latter information, lymph
node biopsies of PTCL-NOS could not be reliably distinguished
from adult T-cell leukemia/lymphoma. Because this disease also
occurs in the West, HTLV-1 status should be evaluated and reported
to the pathologist in patients at high risk for the disease or from
endemic areas. Two other diagnoses, angioimmunoblastic T-cell
lymphoma and enteropathy-associated T-cell lymphoma, were also
sometimes clarified by the clinical information. These findings
highlight some of the difficulties in the differential diagnosis of
PTCL subtypes, particularly for cases at the border between
different entities. For such cases, gene expression profiling may be
very helpful in the future for confirming the correct diagnosis.24-27
The clinical features of our patients with PTCL-NOS are similar
to those reported by other studies.5-13,20,23,28 The median age of our
patients was 60 years (range, 19-87 years), with a male predomi-
nance, and the majority of the patients (69%) presented with
advanced stage disease. Most of our patients (87%) presented with
nodal disease, but extranodal disease was also present in 49% of
these patients, whereas only 13% presented with extranodal disease
only. As in other studies,5-13,20-23,28 the majority of our patients
(80%) were treated with combination chemotherapy including an
anthracycline, but the complete remission rate was low (56%) and
there were few cures, with no survival advantage for those
receiving an anthracycline. The 5-year OS (32%) and FFS (20%) of
the patients in our series were poor, but in keeping with the survival
reported in other studies.5-13,20-23,28 The use of more intensified
chemotherapy in patients with PTCL-NOS does not appear to be
beneficial,7,11 although one study reported improved survival.12
Therefore, new treatment regimens are clearly needed for PTCL-
NOS, including the addition of novel agents to existing regimens,
new regimens combining novel agents, use of monoclonal antibod-
ies, and innovative strategies for stem cell transplantation.29-32 We
did find that initial radiation therapy improved the survival of
patients with stage 1 disease who also received chemotherapy
compared with those who received only chemotherapy, similar to
the experience with diffuse large B-cell lymphoma.33,34 However,
our study was retrospective in nature and selection bias may have
been present.
To apply and evaluate new treatment strategies for PTCL-NOS,
reliable clinical and pathologic prognostic factors are needed for a
rational and risk-adapted approach. Although a small number of
studies5,7-13 have attempted to identify the clinical features of
prognostic importance in PTCL-NOS, these studies have gener-
ally consisted of small numbers of cases and the findings have
been inconsistent or unconfirmed. In our study, all of the
prognostic factors in the IPI were highly significant predictors
of OS and FFS (P  .001), and the IPI was predictive of both OS
and FFS (Figure 3). However, only patients with an IPI score of
0 or 1 had a favorable FFS. These findings regarding the IPI have,
Figure 5. OS of patients with the lymphoepithelioid (Lennert) variant of
PTCL-NOS (n  28) compared with the unspecified cases of PTCL-NOS
(n  292).
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in general, been confirmed by the other studies.5,7-9,11-13 We also
identified several other clinical prognostic factors by univariate
analysis, but only bulky disease ( 10 cm) and thrombocytopenia
( 150 109/L) were independent predictors of survival when
controlling for the IPI. However, other studies performing multivar-
iate analysis with the IPI in PTCL-NOS did not evaluate these
2 clinical features, and no other consistent findings were re-
ported.5,9,11,13 In another study, bulky disease dropped out in
multivariate analysis.10 Therefore, we think that the IPI, along with
bulky disease and thrombocytopenia, could be used to stratify
patients with PTCL-NOS for novel and risk-adapted therapies.
In 2004, Gallamini et al proposed a new PIT that incorporated 3
parameters of the IPI: age more than 60 years, performance status
 2, and elevated serum lactate dehydrogenase, as well as bone
marrow involvement.9 Although they found the IPI to be highly
predictive of OS (P  .001), they concluded that the PIT was
superior to the IPI. One concern about the PIT is that the local
diagnosis of record was used in development of the model and
the diagnosis of PTCL-NOS was not confirmed by an expert
hematopathologist. However, others have also found the PIT to
be predictive of survival in PTCL-NOS.10,12,13 In our study,
however, the PIT does not appear to be superior to the IPI
(Figure 4, Table 3). Using a similar strategy, but with a small
number of cases, Kojima et al8 and Went et al10 have also
proposed new prognostic models for PTCL-NOS, but these
models have not been validated by others.
We also evaluated a variety of pathologic features as possible
prognostic factors in PTCL-NOS. In our study, Ki67 proliferation
( 25%) was an adverse predictor of survival. Ki67 proliferation
( 80%) was also reported by Went et al to predict for poor
survival and was incorporated into their prognostic model.10 We
also found that a high number of transformed tumor cells ( 70%)
was predictive of poor survival, which has previously been
reported by others.6,19 Dupuis et al have shown that the presence of
EBV-encoded RNAs (EBERs) in the tumor tissue is an adverse
predictor of survival in older patients ( 60 years) with PTCL-
NOS.35 In contrast, we found that significant EBV infection
(EBERs 3-4) was predictive of poor survival only in our younger
patients ( 60 years). Some studies have reported that a T-helper
cell phenotype (CD4, CD8	) predicts for better survival, but we
could not confirm this finding.8,10 Asano et al have reported that a
cytotoxic phenotype (ie, the expression of TIA-1 or granzyme B) is
predictive of poor survival in PTCL-NOS, but EBV was also found
in 51% of their cases with a cytotoxic phenotype.36 We and
others10,37 could not confirm that a cytotoxic phenotype is an
adverse prognostic factor in PTCL-NOS. However, Iqbal et al,
using gene expression profiling, recently identified a molecular
subgroup among PTCL-NOS with features of cytotoxic lympho-
cytes and a poor survival.26 Additional studies are needed to clarify
these discrepant findings in PTCL-NOS.
We also found 2 pathologic features that were favorable
predictors of survival in PTCL-NOS, a high background of reactive
CD8 T cells ( 10%) and the lymphoepithelioid (Lennert) variant
of PTCL-NOS, which is characterized by a high content of
epithelioid histocytes in clusters. These findings suggest that the
tumor microenvironment may play an important role in the biology
of some cases of PTCL-NOS. The excellent survival of our cases of
lymphoepithelioid lymphoma could not be explained by other
clinical prognostic factors, although these cases were generally
characterized by atypical small lymphoid cells with few trans-
formed tumor cells admixed. However, others38,39 have reported a
poor survival for patients with lymphoepithelioid lymphoma. The
characteristic morphology and phenotype of lymphoepithelioid
lymphoma, which is often derived from CD8 cytotoxic T cells,37
as well as the good survival suggest that this special variant of
PTCL-NOS should be further studied and possibly separated as a
distinctive entity in future lymphoma classifications.
Multivariate analysis of the pathologic prognostic factors was
also performed and, when controlling for the IPI, only the number
of transformed tumor cells ( 70%) was predictive of survival.
In a final multivariate analysis of the significant clinical and
pathologic prognostic factors, when controlling for the IPI, only
the number of transformed tumor cells remained predictive of
OS and FFS. This feature also appears to be reproducible
because the expert pathologists were correct in their estimate of
transformed tumor cells more than 70% in 88% of the cases.
Thus, the IPI and this one simple and easy to evaluate pathologic
feature could be used to stratify patients with PTCL-NOS for
novel and risk-adapted therapies.
As our knowledge of the molecular and genetic features of
PTCL evolves in the future, new entities within the heterogeneous
category of PTCL-NOS will be discovered. For example, the recent
study of Iqbal et al, using gene expression profiling, identified a
molecular subgroup with the features of cytotoxic T cells and a
poor outcome compared with other cases of PTCL-NOS.26 New
and better molecular and genetic prognosticators will also be
developed for the various PTCL entities, such as that recently
reported for angioimmunoblastic T-cell lymphoma.26 Hopefully,
new discoveries will also lead to more rational and effective
targeted therapies for the various PTCL entities in the future.
Acknowledgments
The authors thank Martin Bast and Fred Ullrich for the data
collection and analysis, and Ventana Medical Systems Inc (Tucson,
AZ) for donation of the use of a Ventana XT immunostainer for the
project.
A complete list of study sites and physicians participating in the
International Peripheral T-cell Lymphoma Project appears in the
supplemental Appendix.
Authorship
Contribution: D.D.W. designed the research, collected the data,
contributed material and reagents, participated in the pathology
review, analyzed and interpreted the data, and wrote the manu-
script; K.J.S. collected and interpreted the data; N.L.H., R.D.G.,
and E.S.J. contributed material, participated in the pathology
review, and interpreted the data; K.A.M., T.R., S.P., and S.N.
contributed material and reagents, collected data, performed re-
search, and participated in the pathology review; B.N., E.C., and
F.B. contributed material and participated in the pathology review;
B.C., W.-S.K., H.H., M.F., W.Y.A., and K.T. collected and inter-
preted the data; and J.O.A. and J.M.V. designed the research and
collected, analyzed, and interpreted the data.
Conflict-of-interest disclosure: The authors declare no compet-
ing financial interests.
Correspondence: Dennis D. Weisenburger, Department of Pa-
thology and Microbiology, University of Nebraska Medical Center,
983135 Nebraska Medical Center, Omaha, NE 68198-3135; e-
mail: dweisenb@unmc.edu.
PERIPHERAL T-CELL LYMPHOMA, NOS 3407BLOOD, 24 MARCH 2011  VOLUME 117, NUMBER 12
For personal use only.on December 4, 2015. by guest  www.bloodjournal.orgFrom 
References
1. Swerdlow SH, Campo E, Harris NL, et al, eds.
WHO Classification of Tumours of Haematopoi-
etic and Lymphoid Tissues. Lyon, France: Inter-
national Agency for Research on Cancer; 2008.
2. Anderson JR, Armitage JO, Weisenburger DD.
Epidemiology of the non-Hodgkin’s lymphomas:
distributions of the major subtypes differ by geo-
graphic locations. Ann Oncol. 1998;9(7):717-720.
3. Morton LM, Wang SS, Devesa SS, Hartge P,
Weisenburger DD, Linet MS. Lymphoma inci-
dence patterns by WHO subtype in the United
States, 1992-2001. Blood. 2006;107(1):265-276.
4. Abouyabis AN, Shenoy PJ, Lechowicz NJ,
Flowers CR. Incidence and outcomes of periph-
eral T-cell lymphoma subtypes in the United
States. Leuk Lymphoma. 2008;49(11):2099-
2107.
5. Lopez-Guillermo A, Cid J, Salar A, et al. Periph-
eral T-cell lymphomas: initial features, natural his-
tory, and prognostic factors in a series of 174 pa-
tients diagnosed according to the REAL
classification. Ann Oncol. 1998;9(8):849-855.
6. Ru¨diger T, Weisenburger DD, Anderson JR, et al.
Peripheral T-cell lymphoma (excluding anaplastic
large-cell lymphoma): results from the Non-Hodg-
kin’s Lymphoma Classification Project. Ann On-
col. 2002;13(1):140-149.
7. Savage KJ, Chhanabhai M, Gascoyne RD,
Connors JM. Characterization of peripheral T-cell
lymphomas in a single North American institution
by the WHO classification. Ann Oncol. 2004;
15(10):1467-1475.
8. Kojima H, Hasegawa Y, Suzukawa K, et al. Clini-
copathological features and prognostic factors of
Japanese patients with “peripheral T-cell lym-
phoma, unspecified” diagnosed according to the
WHO classification. Leuk Res. 2004;28(12):1287-
1292.
9. Gallamini A, Stelitano C, Calvi R, et al. Peripheral
T-cell lymphoma unspecified (PTCL-U): a new
prognostic model from a retrospective multicen-
tric clinical study. Blood. 2004;103(7):2474-2479.
10. Went P, Agostinelli C, Gallamini A, et al. Marker
expression in peripheral T-cell lymphoma: a pro-
posed clinical-pathologic prognostic score. J Clin
Oncol. 2006;24(16):2472-2479.
11. Prochazka V, Trneny M, Pytlik R, et al. Peripheral
T-cell lymphoma, unspecified: the analysis of the
data from the Czech Lymphoma Study Group
(CLSG) registry. Biomed Pap Med Fac Univ
Palacky Olomouc Czech Repub. 2007;151(1):
103-107.
12. Niitsu N, Okamoto M, Nakamine H, Aoki S,
Motomura S, Hirano M. Clinico-pathologic fea-
tures and outcome of Japanese patients with pe-
ripheral T-cell lymphomas. Hematol Oncol. 2008;
26(3):152-158.
13. Lee Y, Uhm JE, Lee HY, et al. Clinical features
and prognostic factors of patients with “peripheral
T-cell lymphoma, unspecified.” Ann Hematol.
2009;88(2):111-119.
14. International Non-Hodgkin’s Lymphoma Prognos-
tic Factors Project. A predictive model for aggres-
sive non-Hodgkin’s lymphoma: the International
Non-Hodgkin’s Lymphoma Prognostic Factors
Project. N Engl J Med. 1993;329(14):987-994.
15. Kaplan EL, Meier P. Nonparametric estimation
from incomplete observations. J Am Stat Assoc.
1958;53(282):457-481.
16. Cox DR. Regression models and life tables. J R
Stat Soc B. 1972;34(2):187-220.
17. Vose J, Armitage J, Weisenburger D. Interna-
tional Peripheral T-cell and Natural Killer/T-Cell
Lymphoma Study: pathology findings and clinical
outcomes. J Clin Oncol. 2008;26(25):4124-4130.
18. Non-Hodgkin’s Lymphoma Classification Project.
A clinical evaluation of the International Lym-
phoma Study Group classification of non-Hodg-
kin’s lymphoma. Blood. 1997;89(11):3909-3918.
19. Ascani S, Zinzani PL, Gherlinzoni F, et al. Periph-
eral T-cell lymphomas: Clinico-pathologic study of
168 cases according to the REAL classification.
Ann Oncol. 1997;8(6):583-592.
20. Pellatt J, Sweetenham J, Pickering RM, Brown L,
Wilkins B. A single-centre study of treatment out-
comes and survival in 120 patients with periph-
eral T-cell non-Hodgkin’s lymphoma. Ann Hema-
tol. 2002;81(5):267-272.
21. Kim K, Kim WS, Jung CW, et al. Clinical features
of peripheral T-cell lymphomas in 78 patients di-
agnosed according to the Revised European-
American Lymphoma (REAL) classification. Eur J
Cancer. 2002;38(1):75-81.
22. Arrowsmith ER, Macon WR, Kinney MC, et al.
Peripheral T-cell lymphomas: clinical features and
prognostic factors of 92 cases defined by the Re-
vised European-American Lymphoma classifica-
tion. Leuk Lymphoma. 2003;44(2):241-249.
23. Au WY, Ma SY, Chim CS, et al. Clinicopathologic
features and treatment outcome of mature T-cell
and natural killer-cell lymphomas diagnosed ac-
cording to the World Health Organization classifi-
cation scheme: a single center experience of
10 years. Ann Oncol. 2005;16(2):206-214.
24. de Laval L, Bisig B, Thielen C, Boniver J, Gaulard P.
Molecular classification of T-cell lymphomas. Crit
Rev Oncol Hematol. 2009;72(2):125-143.
25. Costello R, Sanchez C, Le Treut T, Rihet P,
Imbert J, Sebahoun G. Peripheral T-cell lym-
phoma gene expression profiling and potential
therapeutic exploitations. Br J Haematol. 2010;
150(1):21-27.
26. Iqbal J, Weisenburger DD, Greiner TC, et al. Mo-
lecular signatures to improve diagnosis in periph-
eral T-cell lymphoma and prognostication in an-
gioimmunoblastic T-cell lymphoma. Blood. 2010;
115(5):1026-1036.
27. Piva R, Agnelli L, Pellegrino E, et al. Gene ex-
pression profiling uncovers molecular classifiers
for the recognition of anaplastic large-cell lym-
phoma within peripheral T-cell neoplasms. J Clin
Oncol. 2010;28(9):1583-1590.
28. Sonnen R, Schmidt WP, Mu¨ller-Hermelink HK,
Schmitz N. The International Prognostic Index
determines the outcome of patients with nodal
mature T-cell lymphomas. Br J Haematol. 2005;
129(3):366-372.
29. Rodriguez J, Gutierrez A, Martinez-Delgado B,
Perez-Manga G. Current and future aggressive
peripheral T-cell lymphoma treatment paradigms,
biological features and therapeutic molecular tar-
gets. Crit Rev Oncol Hematol. 2009;71(3):181-
198.
30. Zain JM, O’Connor O. Targeted treatment and
new agents in peripheral T-cell lymphoma. Int
J Hematol. 2010;92(1):33-44.
31. Foss FM. Enhancing existing approaches to pe-
ripheral T-cell lymphoma. Semin Hematol. 2010;
47(suppl 1):S8-S10.
32. Zinzani PL. High-dose therapy and stem cell
transplantation. Semin Hematol. 2010;47(suppl
1):S15-S17.
33. Persky DO, Miller TP. Localized large cell lym-
phoma: is there any need for radiation therapy?
Curr Opin Oncol. 2009;21(5):401-406.
34. Phan J, Mazloom A, Medeiros LJ, et al. Benefit of
consolidative radiation therapy in patients with
diffuse large B-cell lymphoma treated with
R-CHOP chemotherapy. J Clin Oncol. 2010;
28(27):4170-4176.
35. Dupuis J, Emile JF, Mounier N, et al. Prognostic
significance of Epstein-Barr virus in nodal periph-
eral T-cell lymphoma, unspecified: a Group
d’Etude des Lymphomes de l’Adulte (GELA)
study. Blood. 2006;108(13):4163-4169.
36. Asano N, Suzuki R, Kagami Y, et al. Clinicopatho-
logic and prognostic significance of cytotoxic mol-
ecule expression in nodal peripheral T-cell lym-
phoma, unspecified. Am J Surg Pathol. 2005;
29(10):1284-1293.
37. Geissinger E, Odenwald T, Lee SS, et al. Nodal
peripheral T-cell lymphomas and, in particular,
their lymphoepithelioid (Lennert’s) variant are
often derived from CD8 cytotoxic T cells. Vir-
chows Arch. 2004;445(4):334-343.
38. Patsouris E, Engelhard M, Zwingers T, Lennert K.
Lymphoepithelioid cell lymphoma (Lennert’s lym-
phoma): clinical features derived from analysis of
108 cases. Br J Haematol. 1993;84(2):346-348.
39. Gisselbrecht C, Gaulard P, Lepage E, et al. Prog-
nostic significance of T-cell phenotype in aggres-
sive non-Hodgkin’s lymphomas. Blood. 1998;92(1):
76-82.
3408 WEISENBURGER et al BLOOD, 24 MARCH 2011  VOLUME 117, NUMBER 12
For personal use only.on December 4, 2015. by guest  www.bloodjournal.orgFrom 






Y. Au, Kensei Tobinai, James O. Armitage, Julie M. Vose and for the International Peripheral T-cell 
Campo, Francoise Berger, Bertrand Coiffier, Won-Seog Kim, Harald Holte, Massimo Federico, Wing
Kenneth A. MacLennan, Thomas Rüdiger, Stefano Pileri, Shigeo Nakamura, Bharat Nathwani, Elias 
Dennis D. Weisenburger, Kerry J. Savage, Nancy Lee Harris, Randy D. Gascoyne, Elaine S. Jaffe,
 
cases from the International Peripheral T-cell Lymphoma Project
Peripheral T-cell lymphoma, not otherwise specified: a report of 340
 
http://www.bloodjournal.org/content/117/12/3402.full.html
Updated information and services can be found at:
 (2168 articles)Lymphoid Neoplasia    
 (3487 articles)Free Research Articles    
 (4213 articles)Clinical Trials and Observations    
Articles on similar topics can be found in the following Blood collections
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests
Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints
Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml
Information about subscriptions and ASH membership may be found online at:
  
Copyright 2011 by The American Society of Hematology; all rights reserved.
of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036.
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society
For personal use only.on December 4, 2015. by guest  www.bloodjournal.orgFrom 
